Answers are grounded in this paper and cite their sources.
Integrative analysis reveals anticancer mechanisms of tetrabromo thia-bridged diquinoline, indicating potential therapeutic pathways.
The present study integrated supramolecular analysis with a range of in silico approaches, including crystal structure determination, target prediction, ADMET (absorption, distribution, metabolism, and excretion) profiling, network pharmacology, and molecular docking to investigate the anticancer potential of compound 3 (tetrabromothia-bridged diquinoline). In the solid state, Compound 3 was found to incorporate p-xylene, yielding a stable inclusion complex [(3)2. (p-xylene)], the structure of which was elucidated and interpreted through the lenses of crystal engineering and supramolecular chemistry. Moreover, compound 3 exhibited favourable drug-likeness and strong predicted binding affinity for EGFR and ERBB2 (HER2), suggesting that modulation of EGFR tyrosine kinase inhibitor resistance, along with ERBB signalling pathways, may underpin its potential anticancer activity.
No takes yet. Share an insight, caveat, or question.
Alshahateet et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: